Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.
M Angelyn BethelRobert J MentzPeter MerrillJohn B BuseJuliana Chung Ngor ChanShaun G GoodmanNayyar IqbalNeli JakubonieneBrian KatonaYuliya LokhnyginaRenato D LopesAldo P MaggioniPeter OhmanTsvetalina TankovaGeorge L BakrisAdrian F HernandezRury R HolmanPublished in: Diabetes care (2019)
EQW had no impact on unadjusted retinopathy or renal outcomes. CV risk was modestly reduced only in those with eGFR ≥60 mL/min/1.73 m2 in analyses unadjusted for multiplicity.